BidaskClub upgraded shares of Athenex (NASDAQ:ATNX) from a sell rating to a hold rating in a report released on Thursday.

ATNX has been the subject of several other reports. JPMorgan Chase & Co. began coverage on Athenex in a research report on Wednesday, October 18th. They issued a neutral rating and a $22.20 price objective for the company. Deutsche Bank set a $20.00 target price on Athenex and gave the company a buy rating in a research note on Wednesday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $27.64.

Athenex (ATNX) traded up $0.12 on Thursday, hitting $17.33. The stock had a trading volume of 221,469 shares, compared to its average volume of 198,531. Athenex has a 12 month low of $11.21 and a 12 month high of $20.79. The company has a market capitalization of $1,010.00 and a PE ratio of -6.28.

Athenex (NASDAQ:ATNX) last posted its quarterly earnings data on Thursday, November 9th. The company reported ($0.30) earnings per share for the quarter. analysts predict that Athenex will post -2.75 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Jaffetilchin Investment Partners LLC acquired a new position in shares of Athenex in the fourth quarter valued at $1,711,000. California State Teachers Retirement System acquired a new position in shares of Athenex in the third quarter valued at $198,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Athenex in the third quarter valued at $524,000. Bank of New York Mellon Corp raised its stake in shares of Athenex by 106.7% in the third quarter. Bank of New York Mellon Corp now owns 31,002 shares of the company’s stock valued at $543,000 after purchasing an additional 16,002 shares in the last quarter. Finally, Gilder Gagnon Howe & Co. LLC acquired a new position in shares of Athenex in the third quarter valued at $1,559,000. Institutional investors and hedge funds own 2.93% of the company’s stock.

WARNING: “Athenex (ATNX) Raised to “Hold” at BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Analyst Recommendations for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with's FREE daily email newsletter.